

*Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.*



June 20, 2025

To whom it may concern

Company name: PALTAC CORPORATION  
 Name of representative: Takuya Yoshida,  
 Representative Director, President  
 (Securities code: 8283; TSE Prime Market)  
 Inquiries: Masaharu Shimada,  
 Director, Senior Managing Executive  
 Officer, General Manager of  
 Management Planning Headquarters  
 (Telephone: +81-6-4793-1090)

### **Matters Concerning Controlling Shareholders, Etc.**

PALTAC CORPORATION (the “Company”) hereby announces that, with regard to MEDIPAL HOLDINGS CORPORATION, which is a parent company of the Company, the matters concerning controlling shareholders, etc. are as described below.

1. Trade name, etc. of parent company, controlling shareholder (excluding parent company), other affiliated company or parent company of other affiliated company

(As of March 31, 2025)

Name	Attribute	Ratio of voting rights held (%)			Financial instruments exchange, etc., on which the issued shares, etc., are listed
		Voting rights directly held	Voting rights subject to aggregation	Total	
MEDIPAL HOLDINGS CORPORATION	Parent company	51.68	—	51.68	Prime Market of Tokyo Stock Exchange, Inc.

2. Positioning of the Company in the corporate group centering on the parent company, etc., and the relationships between other listed companies and the parent company, etc.

MEDIPAL HOLDINGS CORPORATION is the parent company holding a majority of the Company’s voting rights. The parent company group aims to contribute to society through the distribution of “Pharmaceuticals, Health, and Beauty” and is engaged in the main businesses of “Prescription Pharmaceutical Wholesale Business,” “Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business,” and “Animal Health Products and Food Processing Raw Materials Wholesale and Related Business.” The Company is exclusively responsible for the “Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business,” and there is no competitive relationship between the Company and the parent company group, and the Company conduct own business activities independently without being influenced by the parent company nor the group companies.

From the viewpoint of corporate governance, the Company makes all decisions on matters such as business strategy and personnel policy on the basis of independent and autonomous discussions at the Company and the management decision made by the Board of Directors of the Company is the final decision within the parent company’s group. In addition, as a listed company with a parent company, the Company is proactively promoting

the appointment of independent outside directors in order to establish an appropriate governance system. The Board of Directors consists of 13 members, of which seven members are independent outside directors, making up the majority.

Furthermore, in order to avoid the appearance of conflicts of interest between the parent company and the minority shareholders, and thus to enhance corporate governance, through implementing appropriate oversight and supervision of the Company's transactions with the controlling shareholder, the Company has established an independent committee as an advisory body to the Board of Directors. This committee is composed exclusively of independent outside directors and outside auditors.

At the same time, the parent company respects the Company's independency and protection of minority shareholders of the Company. Based on the "Group Company Management Regulations," the parent company believes it's desirable, from the perspective of group management, for the Company to improve its corporate value through actively pursuing business development by autonomous funding and quick decision-making. Furthermore, the regulations state that the Company's Board of Directors is final decision-making organ.

In order to optimize the balance between independence as a listed company and group governance, the Company has appointed one director from the parent company to the Board of the Company. Additionally, one director of the Company serves as a director of the parent company.

As stated above, the Company believes that a certain degree of independence from the parent company group has been secured.

### 3. Matters concerning transactions with controlling shareholder, etc.

Fiscal year ended March 31, 2025 (April 1, 2024 - March 31, 2025)

Attribute	Name of company	Location	Capital stock (Millions of yen)	Voting rights (Held) (%)	Relationship with related parties	Details of transactions	Transaction amount (Millions of yen)	Account	Balance at end of term (Millions of yen)
Parent company	MEDIPAL HOLDINGS CORPORATION	Chuo-ku, Tokyo	22,398	(Held) Direct 51.68	Payment and receipt of insurance premium, etc. Concurrent directorships, etc.	Payment of insurance premium	15	—	—
						Receipt of insurance proceeds, etc.	10	—	—

(Notes) 1. Transaction amounts do not include consumption taxes.

2. Details of transactions

Payment of insurance premium and receipt of insurance proceeds, etc., are related to group insurance and are paid or received through the contact point of parent company.

### 4. Status of implementation of measures to protect minority shareholders in transactions, etc., with controlling shareholders

The terms and conditions of transactions with controlling shareholders shall be reasonably determined on the basis of objective information and after sufficient confirmation that they do not differ materially from the general terms and conditions of transactions.